Patients (>/= 12 years) Residual or Recurrent Grade 2 Glioma with confirmed IDH1 (IDH1 R132H/C/G/S/L mutation variants tested) or IDH2 (IDH2 R172K/M/W/S/G mutation variants tested) gene mutation status disease. This evidence concerns the gene IDH1 and central nervous system cancer.